|Company name||CV Sciences, Inc.|
|Class period||July 19, 2018 – August 20, 2018|
|Lead plaintiff deadline||October 23, 2018|
|Court||Southern District of Nevada|
NEW YORK, August 29, 2018 – Bragar Eagel & Squire, P.C. announces that a class action lawsuit has been filed in the U.S. District Court for the Nevada on behalf of all persons or entities who purchased or otherwise acquired CV Sciences, Inc.(Other OTC: CVSI) securities between July 19, 2018 and August 20, 2018, (the “Class Period”). Investors have until October 23, 2018 to apply to the Court to be appointed as lead plaintiff in the lawsuit.
The Complaint alleges that throughout the Class Period, Defendants made false and/or misleading statements, as well as failed to disclose material adverse facts about the Company’s business, operations, and prospects. Specifically, Defendants failed to disclose that its Patent #15/426,617: (1) received a non-final rejection from the USPTO on April 27, 2017; (2) a final rejection from the USPTO on December 14, 2017; and (3) as a result of the foregoing, Defendants’ statements about CV Sciences’ business, operations, and prospects, were materially false and/or misleading and/or lacked a reasonable basis.
If you purchased CV Sciences securities during the Class Period or continue to hold shares purchased before the Class Period, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Melissa Fortunato by email at email@example.com, or telephone at (212) 355-4648, or by filling out the contact form below. There is no cost or obligation to you.